Updated:
Rhythm Pharmaceuticals
David Meeker leads Rhythm Pharmaceuticals, a biotech focused on rare MC4R-pathway obesity disorders.
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals incorporated in 2008 as a biopharmaceutical company focused on rare genetic disorders of obesity. CEO David Meeker, a physician and former Genzyme executive, took the helm in 2017 ahead of the firm's pivot toward commercial-stage operations. The company's foundational asset emerged from a license with Ipsen for setmelanotide, a melanocortin-4 receptor (MC4R) agonist designed to restore impaired signaling in the leptin-melanocortin pathway — a biological circuit central to hunger and energy expenditure. Rhythm went public in 2017 and secured FDA approval for IMCIVREE (setmelanotide) in November 2020 for chronic weight management in patients with POMC, PCSK1, or LEPR deficiency obesity. The company deploys capital into clinical development, genetic screening programs, and global commercial expansion for IMCIVREE. Asset-class focus is narrow — pharmaceutical R&D for peptide therapeutics targeting the MC4R pathway. Rhythm has expanded the approved label twice: first to include Bardet-Biedl syndrome in 2022, and subsequently to pediatric patients as young as six. The firm licenses setmelanotide from Ipsen for all indications and manages a wholly owned subsidiary, Rhythm Pharmaceuticals UK Ltd. The geographic footprint spans the United States and more than 15 European countries, with additional commercial infrastructure in Japan and the Middle East. Preclinical programs include RM-718, a weekly MC4R agonist, and RM-853, an oral MC4R agonist (per the firm's pipeline disclosures, 2024). The firm reported deploying $151.1 million in R&D expenses and $121.5 million in SG&A for fiscal year 2023, reflecting the cost structure of a rare-disease commercial launch. Headcount is not publicly broken out. Rhythm maintains an at-the-market equity offering program to fund operations and ended 2023 with $298.4 million in cash and equivalents (per the firm's 10-K, fiscal 2023). May 2024: David Meeker presented data from a Phase 3 trial evaluating setmelanotide in hypothalamic obesity, showing statistically significant BMI reduction at 52 weeks (per the firm's press release, May 2024). Rhythm differs structurally from diversified biopharma platforms by operating as a single-pathway company — all pipeline assets target the MC4R receptor. This concentrated risk architecture demands clinical execution precision but creates potential for deep biologics expertise that multi-indication competitors rarely match. The firm licenses its core compound rather than owning it outright, adding a royalty obligation to Ipsen that shapes margin profile and long-term return on R&D investment.
General information
Firm type
Asset Manager
Year founded
2008
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Principals
David Meeker
Chief Executive Officer
Sector focus
Frequently asked questions
What does IMCIVREE treat, and how is the drug's mechanism distinct from GLP-1 agonists?
IMCIVREE (setmelanotide) activates the melanocortin-4 receptor (MC4R), the downstream target of leptin signaling that regulates hunger and energy expenditure. It is approved for chronic weight management in patients with confirmed POMC, PCSK1, or LEPR deficiency, as well as Bardet-Biedl syndrome — single-gene disorders where the MC4R pathway is impaired. Unlike GLP-1 agonists such as semaglutide or tirzepatide, setmelanotide addresses a specific genetic defect upstream of appetite regulation rather than broadly suppressing hunger. The drug requires genetic testing confirmation before prescribing and is administered as a daily subcutaneous injection.
Who runs investment or capital allocation decisions at Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals is a public company (NASDAQ: RYTM), not an investment firm or family office. Capital allocation decisions fall to CEO David Meeker and CFO Hunter Smith, with oversight from the board of directors. As an operating biotech, the firm deploys capital primarily into clinical development, regulatory filings, and commercial infrastructure for IMCIVREE and its pipeline candidates.
Does Rhythm Pharmaceuticals generate revenue, and what is its cash position?
Yes, Rhythm generates commercial revenue from IMCIVREE prescriptions and has reported increasing quarterly sales since FDA approval in 2020. The firm ended fiscal year 2023 with $298.4 million in cash and equivalents (per the firm's 10-K, 2023). An at-the-market equity offering program provides additional access to capital, supplementing product revenue. The firm has historically operated at a net loss as it invests in label expansion and pipeline development.
What is the relationship between Rhythm Pharmaceuticals and Ipsen?
Rhythm licenses setmelanotide from Ipsen S.A., the French pharmaceutical company that originally discovered the compound. The license agreement, signed prior to Rhythm's IPO, grants Rhythm exclusive global rights to develop and commercialize setmelanotide for all indications related to genetic obesity disorders. Rhythm pays royalties to Ipsen on net sales, creating a margin obligation that influences the firm's long-term profitability profile.
Which patient populations does Rhythm explicitly target versus exclude?
Rhythm exclusively targets patients with rare genetic disorders of obesity traceable to the MC4R pathway — specifically POMC, PCSK1, or LEPR deficiency obesity, and Bardet-Biedl syndrome, as confirmed by genetic testing. The firm explicitly does not market IMCIVREE for common obesity or metabolic syndrome. A Phase 3 trial in hypothalamic obesity (acquired following brain tumor surgery or cranial radiation) represents a broader indication expansion, but still targets a defined secondary population rather than the general obesity market.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: